16. Oct 2026
Description
(AWP Alliance News) - Ajinomoto plans to expand its contract drug manufacturing business in gene therapy and advanced pharmaceuticals as a key growth driver through fiscal 2030 and beyond. Collaboration with Forge Biologics includes a jointly developed culture media supplement launched as CELLiST AAV Production Supplement 1 to improve AAV productivity.
The strategy also targets broader AAV applications beyond rare diseases, including obesity, alongside expansion into new therapeutic modalities. Forge operates 20 cGMP manufacturing suites at its Columbus, Ohio, campus and has served more than 60 developers.
Its clients have secured acceptance of 24 INDs and CTAs since 2020, with seven additional filings in development.
https://docs.publicnow.com/E580AEDB706E322CD93770894FA9428138F7FEAF
Disclaimer: This news brief was created using generative artificial intelligence. Ajinomoto Co. Inc. published the original content used to generate this news brief on October 16, 2026, and is solely responsible for the information contained therein.
